|
**Overview**: Thalassemia Profile Panel**Introduction**: The Thalassemia Profile Panel is a diagnostic tool designed for thalassemia screening using whole blood samples. In India, thalassemia carrier rate is ~3-4 percent nationally (higher in Sindhi, Punjabi, Gujarati communities), with beta-thalassemia major causing severe transfusion-dependent anemia in ~10,000-12,000 births/year. High morbidity from under-screening in rural/low-SES populations, limited hematology labs, delayed diagnosis leading to complications or unnecessary transfusions. Per hematology practices aligned with ICMR, National Health Mission, and thalassemia control program guidelines, the test employs spectrophotometry/HPLC/microscopy for 35 hematological/biochemical parameters (hemoglobin, RBC/WBC/platelet count, MCV/MCH/MCHC, HbA2/HbF/Hb electrophoresis, iron studies, ferritin, etc.) over 1â€"2 days with high accuracy, valuable for carrier detection (elevated HbA2 >3.5 percent) and major thalassemia diagnosis. This diagnostic falls under hematological screening and targets individuals with microcytic anemia, family history, or premarital screening, addressing accurate detection to guide counseling, iron therapy differentiation, or prenatal testing. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling comprehensive thalassemia profiling and reducing major disease incidence. Its whole blood-based approach ensures reliable multi-parameter evaluation.**Other Names**: Thal Profile Pnl.**FDA Status**: FDA approved, CLIA certified for biochemistry/hematology/clinical pathology, compliant with 2025 standards.**Historical Milestone**: HPLC + iron studies standard in thalassemia screening; in India, core of control programs.**Purpose**: The test assesses 35 parameters including hemoglobin to guide thalassemia screening, detect carrier/major status, inform counseling/therapy.**Test Parameters**: 1. Hemoglobin, 2. RBC Count, 3. WBC Count, 4. Platelet Count, 5. PCV, 6. MCV, 7. MCH, 8. MCHC, 9. ESR, 10. HbA2, 11. HbF, 12. HbA, 13. Peripheral Smear, 14. Reticulocyte Count, 15. Iron, 16. TIBC, 17. Ferritin, 18. Transferrin Saturation, 19. RDW, 20. MCV/MCH Ratio, 21. RBC Morphology, 22. Hb Electrophoresis, 23. G6PD, 24. Osmotic Fragility, 25. Bilirubin Total, 26. Bilirubin Direct, 27. ALT, 28. AST, 29. ALP, 30. Total Protein, 31. Albumin, 32. Serum Iron, 33. Serum Ferritin, 34. Blood Group, 35. Coombs Test.**Pretest Condition**: No fasting required; patients should have microcytic anemia or family history.**Specimen**: 3 mL EDTA whole blood, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 24 hours with proper handling to preserve cell integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 48 hours at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: Not frozen (fresh sample preferred for hematology/HPLC).**Medical History**: Patients should provide details on anemia, family thalassemia.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of undetected thalassemia including major disease, benefits of screening, and minimal discomfort from blood draw.**Procedural Considerations**: The test involves sample processing using spectrophotometry/HPLC/microscopy by trained personnel to ensure sterile technique and interpret results within 1â€"2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, or hemolysis can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Elevated HbA2 + low MCV/MCH indicates beta-thalassemia carrier; severe anemia + high HbF suggests major, necessitating specialist input.**Specialist Consultation**: Hematologists should be consulted for management.**Additional Supporting Tests**: Molecular testing, family screening for confirmation.**Test Limitations**: Iron deficiency overlap; comprehensive approach required.**References**: Indian Journal of Hematology 2024, Thalassemia Studies India 2023. |
